Key result
Small interfering RNA (siRNA) is being evaluated as a potential therapeutic strategy for the treatment of various cardiovascular diseases, including hypertension, atherosclerosis, and heart failure.
Answers are grounded in this paper and cite their sources.
Small interfering RNA (siRNA) represents a promising therapeutic approach for regulating gene expression in various cardiovascular diseases, including hypertension, atherosclerosis, and heart failure.
Cardiovascular diseases (CVDs) place a heavy burden on the economies of low- and middle-income countries. Comprehensive action requires combining approaches that seek to reduce the risks throughout the entire population with strategies that target individuals at high risk or with established disease. Small interfering RNA (siRNA) as a functional mediator for regulation of gene expression has been evaluated for potential therapeutic targets for the treatment of various cardiovascular diseases such as hypertension, atherosclerosis, heart failure etc. The present review attempts have been made to provide a brief outline of the current understanding of the mechanism of RNAi and the delivery system and describe the therapeutic application of siRNAs and their potential for treating CVDs which are taking a heavy toll on human life.
No takes yet. Share an insight, caveat, or question.
Raghunathan et al. (2012) conducted a review in Cardiovascular diseases. Small interfering RNA (siRNA) was evaluated. Small interfering RNA (siRNA) is being evaluated as a potential therapeutic strategy for the treatment of various cardiovascular diseases, including hypertension, atherosclerosis, and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: